{"id":"NCT02312258","sponsor":"Takeda","briefTitle":"A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-09","primaryCompletion":"2019-08-12","completion":"2022-08-26","firstPosted":"2014-12-09","resultsPosted":"2020-11-10","lastUpdate":"2023-09-21"},"enrollment":706,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Ixazomib","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Ixazomib","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \\[CR\\], very good partial response \\[VGPR\\], or partial response \\[PR\\]) to initial therapy and who have not undergone SCT.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization until PD or death (up to 52 months)","effectByArm":[{"arm":"Placebo","deltaMin":9.4,"sd":null},{"arm":"Ixazomib","deltaMin":17.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":275,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Poland","Portugal","Russia","Serbia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["36130300","33021870"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":276},"commonTop":["Nausea","Diarrhoea","Vomiting","Upper respiratory tract infection","Back pain"]}}